Uses of histone acetyltransferase activators

Abstract

The invention provides methods for enhancing histone acylation, learning, memory and/or cognition in subjects with compound (I) or compositions comprising compound (I), or a pharmaceutically acceptable salt thereof.

1 - 25 . (canceled) 
     
     
         26 . A method for enhancing learning or memory in a subject, which comprises administering to the subject a therapeutically effective amount of compound (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         27 . The method of  claim 26 , wherein the subject is not afflicted with a neurodegenerative condition or disease. 
     
     
         28 . The method of  claim 27 , wherein the neurodegenerative condition or disease is selected from one or more of the group consisting of adrenoleukodystrophy (ALD), alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis (Lou Gehrig's Disease or ALS), ataxia telangiectasia, batten disease (Spielmeyer-Vogt-Sjögren-Batten disease), bovine spongiform encephalopathy (BSE), canavan disease, cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, familial fatal insomnia, frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, lewy body dementia, neuroborreliosis, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple system atrophy, multiple sclerosis, narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion diseases, progressive supranuclear palsy, Rett's syndrome, tau-positive frontotemporal dementia, tau-negative frontotemporal dementia, Refsum's disease, sandhoff disease, Schilder's disease, subacute combined degeneration of spinal cord secondary to pernicious anaemia, spinocerebellar ataxia (multiple types with varying characteristics), spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, and toxic encephalopathy. 
     
     
         29 . The method of  claim 27 , wherein the neurodegenerative condition or disease is Alzheimer's. 
     
     
         30 . The method of  claim 26 , wherein the subject is a mammal. 
     
     
         31 . The method of  claim 26 , wherein the therapeutically effective amount is at least about 1 mg/kg body weight. 
     
     
         32 . The method of  claim 26 , wherein the therapeutically effective amount is at least about 25 mg/kg body weight. 
     
     
         33 . The method of  claim 26 , wherein the therapeutically effective amount is at least about 100 mg/kg body weight. 
     
     
         34 . A method for improving memory retention in a subject, which comprises administering to the subject a therapeutically effective amount of compound (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         35 . The method of  claim 34 , wherein the subject is not afflicted with a neurodegenerative condition or disease. 
     
     
         36 . The method of  claim 35 , wherein the neurodegenerative condition or disease is selected from the group consisting of adrenoleukodystrophy (ALD), alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis (Lou Gehrig's Disease or ALS), ataxia telangiectasia, batten disease (Spielmeyer-Vogt-Sjögren-Batten disease), bovine spongiform encephalopathy (BSE), canavan disease, cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, familial fatal insomnia, frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, lewy body dementia, neuroborreliosis, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple system atrophy, multiple sclerosis, narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion diseases, progressive supranuclear palsy, Rett's syndrome, tau-positive frontotemporal dementia, tau-negative frontotemporal dementia, Refsum's disease, sandhoff disease, Schilder's disease, subacute combined degeneration of spinal cord secondary to pernicious anaemia, spinocerebellar ataxia (multiple types with varying characteristics), spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, and toxic encephalopathy. 
     
     
         37 . The method of  claim 35 , wherein the neurodegenerative condition or disease is Alzheimer's. 
     
     
         38 . The method of  claim 34 , wherein the subject is a mammal. 
     
     
         39 . The method of  claim 34 , wherein the therapeutically effective amount is at least about 1 mg/kg body weight. 
     
     
         40 . The method of  claim 34 , wherein the therapeutically effective amount is at least about 25 mg/kg body weight. 
     
     
         41 . The method of  claim 34 , wherein the therapeutically effective amount is at least about 100 mg/kg body weight.